Abstract
BackgroundAssessment of structural damage progression, clinical efficacy and safety in patients with early-stage rheumatoid arthritis (RA) naïve to methotrexate (MTX) and with poor prognostic factors with certolizumab pegol (CZP) has...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have